Your browser doesn't support javascript.
loading
Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.
Tomita, Y; Motzer, R J; Choueiri, T K; Rini, B I; Miyake, H; Oya, M; Albiges, L; Aizawa, M; Umeyama, Y; Wang, J; di Pietro, A; Schmidinger, M.
Afiliação
  • Tomita Y; Departments of Urology and Molecular Oncology, Niigata University Graduate School of Medicine, Niigata, Japan. Electronic address: ytomita@med.niigata-u.ac.jp.
  • Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Choueiri TK; The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Rini BI; Hematology Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
  • Miyake H; Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Oya M; Department of Urology, Keio University School of Medicine, Tokyo, Japan.
  • Albiges L; Department of Oncology, Institut Gustave Roussy, Villejuif, France.
  • Aizawa M; Pfizer R&D Japan, Tokyo, Japan.
  • Umeyama Y; Pfizer R&D Japan, Tokyo, Japan.
  • Wang J; Pfizer, Cambridge, MA, USA.
  • di Pietro A; Pfizer srl, Milan, Italy.
  • Schmidinger M; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
ESMO Open ; 8(6): 102034, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37866029

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais / Antineoplásicos Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article